Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: a randomised controlled trial. Celecoxib Long-term Arthritis Safety Study.
JAMA, 284 (2000), pp. 1247-1255
[2.]
J.L. Goldstein.
on behalf of CLASS investigators. Gastrointestinal (GI) event rates in the CLASS study: 6 months vs longer-term follow-up analyses.
Gastroenterology, 122 (2002), pp. A-469
[3.]
M. Mamdani, P.A. Rochon, D.N. Juurlink, A. Kopp, G.M. Anderson, G. Naglie, et al.
Observational study of upper gastrointestinal haemorrhage in elderly patients given selective ciclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.
BMJ, 325 (2002), pp. 624-627
[4.]
L.A. García Rodríguez.
por el Grupo de Estudio Patología TDS. El uso de Coxibs no se asocia a aumento de riesgo de hemorragia digestiva alta. VI Congreso de la Asociación Española de Gastroenterología.
Gastroenterol Hepatol, 26 (2003), pp. 183
[5.]
F. Wolfe, J. Anderson, T.A. Burke, L.M. Arguelles, D. Pettitt.
Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
J Rheumatol, 29 (2002), pp. 467-473
[6.]
L.M. Ruilope, A. Coca.
Inhibidores selectivos de la ciclooxigenasa-2 (Coxibs) y morbilidad cardiovascular.
Med Clin (Barc), 118 (2002), pp. 219-221
[7.]
W.A. Ray, T.M. MacDonald, D.H. Solomon, D.J. Graham, J. Avorn.
COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
Pharmacoepi Drug Saf, 12 (2003), pp. 67-70
Copyright © 2003. Sociedad Española de Salud Pública y Administración Sanitaria
